Europe Cardiac Safety Services Market - Industry Trends and Forecast to 2029

Description

List of Tables

Europe cardiac safety services market is projected to register a substantial CAGR of 14.8% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.

Market Segmentation:

Europe Cardiac Safety Services Market, By Services (ECG/Holter Measurements, Blood Pressure Measurements, In Vitro Cardiac Safety Assessment Services, Cardiovascular Imaging, Real-Time Telemetry Monitoring, Central Over-Read of ECGS, Non-Invasive Cardiac Imaging, Physiologic Stress Testing, Thorough QT Studies, TQT and Exposure Response Modeling, Platelet Aggregation and Other Services), Phase (Phase 1, Phase 2 and Phase 3), Type (Integrated Services and Standalone Services), End User (Pharmaceuticals & Biopharmaceuticals Companies, Contract Research Organizations and Academic and Research Institute) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the Europe cardiac safety services market are:

Technological advances in research and development, and drug discovery

Increase in prevalence of cardiovascular diseases

Market Players:

The key market players for Europe cardiac safety services market are listed below:

Koninklijke Philips N.V.

Laboratory Corporation of America Holdings

IQVIA

Medpace

Ncardia

Certara

Eurofins Scientific

SGS SA

Banook

Celerion

Biotrial

Richmond Pharmacology

PhysioStim

1 INTRODUCTION 26

1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 OVERVIEW OF EUROPE CARDIAC SAFETY SERVICES MARKET 26
1.4 LIMITATIONS 27
1.5 MARKETS COVERED 28

2 MARKET SEGMENTATION 30

2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 32
2.4 CURRENCY AND PRICING 32
2.5 DBMR TRIPOD DATA VALIDATION MODEL 33
2.6 MULTIVARIATE MODELLING 36
2.7 SERVICES LIFELINE CURVE 36
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
2.9 DBMR MARKET POSITION GRID 38
2.10 MARKET END USER GRID 40
2.11 VENDOR SHARE ANALYSIS 41
2.12 SECONDARY SOURCES 42
2.13 ASSUMPTIONS 42

3 EXECUTIVE SUMMARY 43

4 PREMIUM INSIGHTS 46

4.1 PORTERS FIVE FORCES 47
4.2 PESTEL ANALYSIS 48

5 EPIDEMIOLOGY 49

5.1 INCIDENCE OF ALL BY GENDER 49
5.2 TREATMENT RATE 50
5.3 MORTALITY RATE 50
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 51

6 INDUSTRY INSIGHT 52

6.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 52
6.2 PATENT ANALYSIS 53
6.3 PATENT FLOW DIAGRAM 54
6.4 KEY PATIENT ENROLLMENT STRATEGIES 54
6.5 PRICING STRATEGY 57

7 EUROPE CARDIAC SAFETY SERVICES MARKET: REGULATIONS 58

8 MARKET OVERVIEW 61

8.1 DRIVERS 63
- 8.1.1 INCREASE IN THE NUMBER OF CLINICAL TRIALS 63
- 8.1.2 INCREASE IN HEALTHCARE EXPENDITURE AND FUNDING 63
- 8.1.3 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 64
- 8.1.4 INCREASE IN R&D ACTIVITIES 64
8.2 RESTRAINTS 65
- 8.2.1 HIGH COST OF CARDIAC SAFETY EVALUATION 65
- 8.2.2 STRICT REGULATORY 65
8.3 OPPORTUNITIES: 66
- 8.3.1 INCREASE IN NEW DRUG DEVELOPMENT 66
- 8.3.2 RISE IN THE EXPANSION OF THE CARDIAC SAFETY SERVICES 67
8.4 CHALLENGES 67
- 8.4.1 TIME-CONSUMING PROCEDURE 67
- 8.4.2 LACK OF SKILLED PERSON TO OPERATE DEVICES DURING CARDIAC SAFETY EVALUATION 68

9 EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES 69

9.1 OVERVIEW 70
9.2 ECG/HOLTER MEASUREMENTS 74
9.3 BLOOD PRESSURE MEASUREMENTS 74
9.4 IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES 75
- 9.4.1 HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS 76
  - 9.4.1.1 1 CONCENTRATIONS 76
  - 9.4.1.2 4 CONCENTRATIONS 76
- 9.4.2 COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) 77
  - 9.4.2.1 3 CONCENTRATIONS 77
  - 9.4.2.2 5 CONCENTRATIONS 77
- 9.4.3 IN VITRO HERG ASSAY 77
- 9.4.4 OTHERS 77
9.5 CARDIOVASCULAR IMAGING 77
9.6 REAL TIME TELEMETRY MONITORING 78
9.7 CENTRAL OVER-READ OF ECGS 79
9.8 NON-INVASIVE CARDIAC IMAGING 79
9.9 PHYSIOLOGIC STRESS TESTING 80
9.10 THOROUGH QT STUDIES 81
9.11 TQT AND EXPOSURE RESPONSE MODELLING 81
9.12 PLATELET AGGREGATION 82
9.13 OTHERS 83

10 EUROPE CARDIAC SAFETY SERVICES MARKET, BY PHASE 84

10.1 OVERVIEW 85
10.2 PHASE I 88
10.3 PHASE II 88
10.4 PHASE III 89

11 EUROPE CARDIAC SAFETY SERVICES MARKET, BY TYPE 90

11.1 OVERVIEW 91
11.2 INTEGRATED SERVICES 94
11.3 STANDALONE SERVICES 95

12 EUROPE CARDIAC SAFETY SERVICES MARKET, BY END USER 96

12.1 OVERVIEW 97
12.2 PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES 100
12.3 CONTRACT RESEARCH ORGANIZATIONS 100
12.4 ACADEMIC AND RESEARCH INSTITUTE 101

13 EUROPE CARDIAC SAFETY SERVICES MARKET, BY REGION 102

13.1 EUROPE 103
- 13.1.1 GERMANY 111
- 13.1.2 FRANCE 114
- 13.1.3 U.K. 117
- 13.1.4 ITALY 120
- 13.1.5 SPAIN 123
- 13.1.6 TURKEY 126
- 13.1.7 RUSSIA 129
- 13.1.8 NETHERLANDS 132
- 13.1.9 SWITZERLAND 135
- 13.1.10 BELGIUM 138
- 13.1.11 REST OF EUROPE 141

14 EUROPE CARDIAC SAFETY SERVICES MARKET: COMPANY LANDSCAPE 142

14.1 COMPANY SHARE ANALYSIS: EUROPE 142

15 COMPANY PROFILE 143

15.1 EUROFINS SCIENTIFIC 143
- 15.1.1 COMPANY SNAPSHOT 143
- 15.1.2 REVENUE ANALYSIS 144
- 15.1.3 COMPANY SHARE ANALYSIS 144
- 15.1.4 PRODUCT PORTFOLIO 144
- 15.1.5 RECENT DEVELOPMENTS 145
  - 15.1.5.1 AGREEMENTS 145
  - 15.1.5.2 ACQUISITION 145
15.2 PPD INC. (SUBSIDIARY OF THERMO FISHER SCIENTIFIC INC) 146
- 15.2.1 COMPANY SNAPSHOT 146
- 15.2.2 REVENUE ANALYSIS 146
- 15.2.3 COMPANY SHARE ANALYSIS 147
- 15.2.4 PRODUCT PORTFOLIO 147
- 15.2.5 RECENT DEVELOPMENT 147
  - 15.2.5.1 INVESTMENT 147
15.3 KONINKLIJKE PHILIPS N.V. 148
- 15.3.1 COMPANY SNAPSHOT 148
- 15.3.2 REVENUE ANALYSIS 148
- 15.3.3 COMPANY SHARE ANALYSIS 149
- 15.3.4 PRODUCT PORTFOLIO 149
- 15.3.5 RECENT DEVELOPMENT 149
  - 15.3.5.1 ACQUISITION 149
15.4 IQVIA 150
- 15.4.1 COMPANY SNAPSHOT 150
- 15.4.2 REVENUE ANALYSIS 150
- 15.4.3 COMPANY SHARE ANALYSIS 151
- 15.4.4 PRODUCT PORTFOLIO 151
- 15.4.5 RECENT DEVELOPMENTS 151
  - 15.4.5.1 ACQUISITION 151
15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS 152
- 15.5.1 COMPANY SNAPSHOT 152
- 15.5.2 REVENUE ANALYSIS 152
- 15.5.3 COMPANY SHARE ANALYSIS 153
- 15.5.4 PRODUCT PORTFOLIO 153
- 15.5.5 RECENT DEVELOPMENTS 153
  - 15.5.5.1 NEW LABORATORY 153
  - 15.5.5.2 ACQUISITION 153
15.6 BANOOK 154
- 15.6.1 COMPANY SNAPSHOT 154
- 15.6.2 PRODUCT PORTFOLIO 154
- 15.6.3 RECENT DEVELOPMENT 154
  - 15.6.3.1 AGREEMENT 154
15.7 BIOTRIAL 155
- 15.7.1 COMPANY SNAPSHOT 155
- 15.7.2 PRODUCT PORTFOLIO 155
- 15.7.3 RECENT DEVELOPMENT 155
  - 15.7.3.1 NEW CENTER OPENING 155
15.8 CELERION 156
- 15.8.1 COMPANY SNAPSHOT 156
- 15.8.2 PRODUCT PORTFOLIO 156
- 15.8.3 RECENT DEVELOPMENT 156
  - 15.8.3.1 NEW CENTER OPENING 156
15.9 CERTARA 157
- 15.9.1 COMPANY SNAPSHOT 157
- 15.9.2 REVENUE ANALYSIS 157
- 15.9.3 PRODUCT PORTFOLIO 158
- 15.9.4 RECENT DEVELOPMENTS 158
  - 15.9.4.1 CONTRACT 158
  - 15.9.4.2 ACQUISITION 158
15.10 CLARIO 159
- 15.10.1 COMPANY SNAPSHOT 159
- 15.10.2 PRODUCT PORTFOLIO 159
- 15.10.3 RECENT DEVELOPMENT 159
  - 15.10.3.1 PRODUCT EXPANSION 159
15.11 MEDPACE 160
- 15.11.1 COMPANY SNAPSHOT 160
- 15.11.2 REVENUE ANALYSIS 160
- 15.11.3 PRODUCT PORTFOLIO 161
- 15.11.4 RECENT DEVELOPMENTS 161
  - 15.11.4.1 ACQUISITION 161
15.12 NCARDIA 162
- 15.12.1 COMPANY SNAPSHOT 162
- 15.12.2 PRODUCT PORTFOLIO 162
- 15.12.3 RECENT DEVELOPMENT 162
  - 15.12.3.1 PARTNERSHIP 162
15.13 NEXEL CO., LTD 163
- 15.13.1 COMPANY SNAPSHOT 163
- 15.13.2 PRODUCT PORTFOLIO 163
- 15.13.3 RECENT DEVELOPMENTS 163
  - 15.13.3.1 JOINT VENTURE 163
  - 15.13.3.2 PARTNERSHIP 164
15.14 PHYSIOSTIM 165
- 15.14.1 COMPANY SNAPSHOT 165
- 15.14.2 PRODUCT PORTFOLIO 165
- 15.14.3 RECENT DEVELOPMENT 165
  - 15.14.3.1 PARTNERSHIP 165
15.15 RICHMOND PHARMACOLOGY 166
- 15.15.1 COMPANY SNAPSHOT 166
- 15.15.2 PRODUCT PORTFOLIO 166
- 15.15.3 RECENT DEVELOPMENT 166
  - 15.15.3.1 EVENT 166
15.16 SGS SA 167
- 15.16.1 COMPANY SNAPSHOT 167
- 15.16.2 REVENUE ANALYSIS 167
- 15.16.3 PRODUCT PORTFOLIO 168
- 15.16.4 RECENT DEVELOPMENT 168
  - 15.16.4.1 ACQUISITION 168
15.17 SHANGHAI MEDICILON INC. 169
- 15.17.1 COMPANY SNAPSHOT 169
- 15.17.2 PRODUCT PORTFOLIO 169
- 15.17.3 RECENT DEVELOPMENTS 169
  - 15.17.3.1 PARTNERSHIP 169
  - 15.17.3.2 PARTNERSHIP 170

16 QUESTIONNAIRE 171

17 RELATED REPORTS 173

LIST OF TABLES

TABLE 1 PROPORTION OF WOMEN IN CLINICAL STUDIES, ACCORDING TO DEVELOPMENT PHASE 41
TABLE 2 PROBABILITY OF SUCCESS BY CLINICAL TRIAL PHASE TO THERAPEUTIC AREA 42
TABLE 3 MORTALITY RATES FROM CLINICAL TRIALS AND EUROPEAN SAFETY AND EXPOSURE SURVEY (ESES), DEATHS PER 100 (PYE) 42
TABLE 4 ADHERENCE RATE TO COMMON CARDIOVASCULAR MEDICATION 43
TABLE 5 PROPORTION OF WOMEN IN CLINICAL STUDIES, ACCORDING TO DEVELOPMENT PHASE 45
TABLE 6 INITIATIVES TO INCREASE ENROLLMENT IN CLINICAL TRIALS AMONG UNDERREPRESENTED POPULATIONS 47
TABLE 7 ESTIMATED COST OF CARDIAC SAFETY EVALUATION DEVICES 49
TABLE 8 EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 65
TABLE 9 EUROPE ECG/HOLTER MEASUREMENTS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 66
TABLE 10 EUROPE BLOOD PRESSURE MEASUREMENTS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 67
TABLE 11 EUROPE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 67
TABLE 12 EUROPE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 68
TABLE 13 EUROPE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 68
TABLE 14 EUROPE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 69
TABLE 15 EUROPE CARDIOVASCULAR IMAGING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 70
TABLE 16 EUROPE REAL TIME TELEMETRY MONITORING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 70
TABLE 17 EUROPE CENTRAL OVER-READ OF ECGS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 71
TABLE 18 EUROPE NON-INVASIVE CARDIAC IMAGING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 72
TABLE 19 EUROPE PHYSIOLOGIC STRESS TESTING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 72
TABLE 20 EUROPE THOROUGH QT STUDIES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 73
TABLE 21 EUROPE TQT AND EXPOSURE RESPONSE MODELLING IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 74
TABLE 22 EUROPE PLATELET AGGREGATION IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 74
TABLE 23 EUROPE OTHERS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 75
TABLE 24 EUROPE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 79
TABLE 25 EUROPE PHASE I IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 80
TABLE 26 EUROPE PHASE II IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 81
TABLE 27 EUROPE PHASE III IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 81
TABLE 28 EUROPE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 85
TABLE 29 EUROPE INTEGRATED SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 86
TABLE 30 EUROPE STANDALONE SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 87
TABLE 31 EUROPE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 91
TABLE 32 EUROPE PHARMACEUTICALS & BIOPHARMACEUTICALS COMPANIES IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 92
TABLE 33 EUROPE CONTRACT RESEARCH ORGANIZATIONS IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 93
TABLE 34 EUROPE ACADEMIC AND RESEARCH INSTITUTE IN CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2029 (USD MILLION) 93
TABLE 35 EUROPE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 100
TABLE 36 EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 100
TABLE 37 EUROPE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 101
TABLE 38 EUROPE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 101
TABLE 39 EUROPE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 101
TABLE 40 EUROPE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 101
TABLE 41 EUROPE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 102
TABLE 42 EUROPE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 102
TABLE 43 GERMANY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 103
TABLE 44 GERMANY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 103
TABLE 45 GERMANY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 104
TABLE 46 GERMANY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 104
TABLE 47 GERMANY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 104
TABLE 48 GERMANY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 104
TABLE 49 GERMANY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 105
TABLE 50 FRANCE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 106
TABLE 51 FRANCE IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 106
TABLE 52 FRANCE HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 107
TABLE 53 FRANCE COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 107
TABLE 54 FRANCE CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 107
TABLE 55 FRANCE CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 107
TABLE 56 FRANCE CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 108
TABLE 57 U.K. CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 109
TABLE 58 U.K. IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 109
TABLE 59 U.K. HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 110
TABLE 60 U.K. COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 110
TABLE 61 U.K. CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 110
TABLE 62 U.K. CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 110
TABLE 63 U.K. CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 111
TABLE 64 ITALY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 112
TABLE 65 ITALY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 112
TABLE 66 ITALY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 113
TABLE 67 ITALY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 113
TABLE 68 ITALY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 113
TABLE 69 ITALY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 113
TABLE 70 ITALY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 114
TABLE 71 SPAIN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 115
TABLE 72 SPAIN IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 115
TABLE 73 SPAIN HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 116
TABLE 74 SPAIN COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 116
TABLE 75 SPAIN CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 116
TABLE 76 SPAIN CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 116
TABLE 77 SPAIN CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 117
TABLE 78 TURKEY CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 118
TABLE 79 TURKEY IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 118
TABLE 80 TURKEY HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 119
TABLE 81 TURKEY COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 119
TABLE 82 TURKEY CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 119
TABLE 83 TURKEY CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 119
TABLE 84 TURKEY CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 120
TABLE 85 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 121
TABLE 86 RUSSIA IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 121
TABLE 87 RUSSIA HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 122
TABLE 88 RUSSIA COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 122
TABLE 89 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 122
TABLE 90 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 122
TABLE 91 RUSSIA CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 123
TABLE 92 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 124
TABLE 93 NETHERLANDS IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 124
TABLE 94 NETHERLANDS HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 125
TABLE 95 NETHERLANDS COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 125
TABLE 96 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 125
TABLE 97 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 125
TABLE 98 NETHERLANDS CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 126
TABLE 99 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 127
TABLE 100 SWITZERLAND IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 127
TABLE 101 SWITZERLAND HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 128
TABLE 102 SWITZERLAND COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 128
TABLE 103 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 128
TABLE 104 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 128
TABLE 105 SWITZERLAND CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 129
TABLE 106 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 130
TABLE 107 BELGIUM IN VITRO CARDIAC SAFETY ASSESSMENT SERVICES IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 130
TABLE 108 BELGIUM HUMAN IPSC-DERIVED CARDIOMYOCYTES MEA ASSAYS IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 131
TABLE 109 BELGIUM COMPREHENSIVE IN VITRO PROARRHYTHMIA ASSAY (CIPA) IN CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 131
TABLE 110 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY PHASE, 2020-2029 (USD MILLION) 131
TABLE 111 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2029 (USD MILLION) 131
TABLE 112 BELGIUM CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2029 (USD MILLION) 132
TABLE 113 REST OF EUROPE CARDIAC SAFETY SERVICES MARKET, BY SERVICES, 2020-2029 (USD MILLION) 133

LIST OF FIGURES

FIGURE 1 EUROPE CARDIAC SAFETY SERVICES MARKET: SEGMENTATION 21
FIGURE 2 EUROPE CARDIAC SAFETY SERVICES MARKET: DATA TRIANGULATION 24
FIGURE 3 EUROPE CARDIAC SAFETY SERVICES MARKET: DROC ANALYSIS 25
FIGURE 4 EUROPE CARDIAC SAFETY SERVICES MARKET: EUROPE VS COUNTRY MARKET ANALYSIS 26
FIGURE 5 EUROPE CARDIAC SAFETY SERVICES MARKET: COMPANY RESEARCH ANALYSIS 26
FIGURE 6 EUROPE CARDIAC SAFETY SERVICES MARKET: INTERVIEW DEMOGRAPHICS 28
FIGURE 7 EUROPE CARDIAC SAFETY SERVICES MARKET: DBMR MARKET POSITION GRID 29
FIGURE 8 EUROPE CARDIAC SAFETY SERVICES MARKET: MARKET END USER GRID 31
FIGURE 9 EUROPE CARDIAC SAFETY SERVICES MARKET: VENDOR SHARE ANALYSIS 32
FIGURE 10 EUROPE CARDIAC SAFETY SERVICES MARKET: SEGMENTATION 36
FIGURE 11 THE INCREASE IN DEMAND FOR CARDIAC SAFETY SERVICES ARE EXPECTED TO DRIVE THE EUROPE CARDIAC SAFETY SERVICES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029 37
FIGURE 12 ECG/HOLTER MEASUREMENTS SUBSTITUTE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE CARDIAC SAFETY SERVICES MARKET IN 2022 & 2029 37
FIGURE 13 PATIENT FLOW DIAGRAM FOR ANY RANDOM DRUG 45
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE CARDIAC SAFETY SERVICES MARKET 53
FIGURE 15 EUROPE CARDIAC SAFETY SERVICES MARKET: BY SERVICES, 2021 61
FIGURE 16 EUROPE CARDIAC SAFETY SERVICES MARKET: BY SERVICES, 2022-2029 (USD MILLION) 62
FIGURE 17 EUROPE CARDIAC SAFETY SERVICES MARKET: BY SERVICES, CAGR (2022-2029) 63
FIGURE 18 EUROPE CARDIAC SAFETY SERVICES MARKET: BY SERVICES, LIFELINE CURVE 64
FIGURE 19 EUROPE CARDIAC SAFETY SERVICES MARKET: BY PHASE, 2021 76
FIGURE 20 EUROPE CARDIAC SAFETY SERVICES MARKET: BY PHASE, 2022-2029 (USD MILLION) 77
FIGURE 21 EUROPE CARDIAC SAFETY SERVICES MARKET: BY PHASE, CAGR (2022-2029) 77
FIGURE 22 EUROPE CARDIAC SAFETY SERVICES MARKET: BY PHASE, LIFELINE CURVE 78
FIGURE 23 EUROPE CARDIAC SAFETY SERVICES MARKET: BY TYPE, 2021 82
FIGURE 24 EUROPE CARDIAC SAFETY SERVICES MARKET: BY TYPE, 2022-2029 (USD MILLION) 83
FIGURE 25 EUROPE CARDIAC SAFETY SERVICES MARKET: BY TYPE, CAGR (2022-2029) 83
FIGURE 26 EUROPE CARDIAC SAFETY SERVICES MARKET: BY TYPE, LIFELINE CURVE 84
FIGURE 27 EUROPE CARDIAC SAFETY SERVICES MARKET: BY END USER, 2021 88
FIGURE 28 EUROPE CARDIAC SAFETY SERVICES MARKET: BY END USER, 2022-2029 (USD MILLION) 89
FIGURE 29 EUROPE CARDIAC SAFETY SERVICES MARKET: BY END USER, CAGR (2022-2029) 89
FIGURE 30 EUROPE CARDIAC SAFETY SERVICES MARKET: BY END USER, LIFELINE CURVE 90
FIGURE 31 EUROPE CARDIAC SAFETY SERVICES MARKET: SNAPSHOT (2021) 95
FIGURE 32 EUROPE CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021) 96
FIGURE 33 EUROPE CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2022 & 2029) 96
FIGURE 34 EUROPE CARDIAC SAFETY SERVICES MARKET: BY COUNTRY (2021 & 2029) 97
FIGURE 35 EUROPE CARDIAC SAFETY SERVICES MARKET: BY SERVICES (2022-2029) 98
FIGURE 36 EUROPE CARDIAC SAFETY SERVICES MARKET: COMPANY SHARE 2021 (%) 133